These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 24969823)

  • 1. Regulation of natural health products in Canada.
    Smith A; Jogalekar S; Gibson A
    J Ethnopharmacol; 2014 Dec; 158 Pt B():507-10. PubMed ID: 24969823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Postmarket surveillance of natural health products in Canada: clinical and federal regulatory perspectives.
    Murty M
    Can J Physiol Pharmacol; 2007 Sep; 85(9):952-5. PubMed ID: 18066142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Governance of natural health products regulation: an iterative process.
    Walji R; Wiktorowicz M
    Health Policy; 2013 Jun; 111(1):86-94. PubMed ID: 23523344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Legislative initiatives in Europe, Canada and the US for market authorization of follow-on biologics.
    Looper YJ
    Curr Opin Drug Discov Devel; 2010 Mar; 13(2):247-56. PubMed ID: 20205058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Herbal medicines: challenges in the modern world. Part 4. Canada and United States.
    Job KM; Kiang TK; Constance JE; Sherwin CM; Enioutina EY
    Expert Rev Clin Pharmacol; 2016 Dec; 9(12):1597-1609. PubMed ID: 27644147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Initial steps in the regulation of generic biological drugs: a comparison of U.S. and Canadian regimes.
    Szeto KJ; Wolanski M
    Food Drug Law J; 2012; 67(2):131-41, i. PubMed ID: 24620416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of traditional herbal medicinal products in Japan.
    Maegawa H; Nakamura T; Saito K
    J Ethnopharmacol; 2014 Dec; 158 Pt B():511-5. PubMed ID: 25043783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Canadian regulatory requirements for recombinant fish vaccines.
    Sethi MS; Gifford GA; Samagh BS
    Dev Biol Stand; 1997; 90():347-53. PubMed ID: 9270863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Official experimental testing of biomedical products. Regulatory frame and importance of for quality, safety and efficacy].
    Vieths S; Seitz R
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2014 Oct; 57(10):1133-8. PubMed ID: 25123139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eliminating barriers to DTC advertising for OTCs and natural health products.
    Kondro W
    CMAJ; 2006 May; 174(11):1547-8. PubMed ID: 16717259
    [No Abstract]   [Full Text] [Related]  

  • 11. Antiperspirant drug products for over-the-counter human use; final monograph. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2003 Jun; 68(110):34273-93. PubMed ID: 12795305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Future development of global regulations of Chinese herbal products.
    Fan TP; Deal G; Koo HL; Rees D; Sun H; Chen S; Dou JH; Makarov VG; Pozharitskaya ON; Shikov AN; Kim YS; Huang YT; Chang YS; Jia W; Dias A; Wong VC; Chan K
    J Ethnopharmacol; 2012 Apr; 140(3):568-86. PubMed ID: 22373513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A descriptive study evaluating Health Canada's risk communications.
    Bateman J; Charrois TL; Gardiner P; Vohra S
    Pharmacoepidemiol Drug Saf; 2011 Oct; 20(10):1104-9. PubMed ID: 21692140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Introduction of direct-to-consumer advertising of prescription drugs in Canada: an opinion survey on regulatory policy.
    Mintzes B; Barer M; Lexchin J; Bassett KL
    Res Social Adm Pharm; 2005 Jun; 1(2):310-30. PubMed ID: 17138480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Canadian and US drug approval times and safety considerations.
    Rawson NS; Kaitin KI
    Ann Pharmacother; 2003 Oct; 37(10):1403-8. PubMed ID: 14519031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Testing of medicinal products produced from pooled plasma].
    Unkelbach U; Hunfeld A; Breitner-Ruddock S
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2014 Oct; 57(10):1181-4. PubMed ID: 25213735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New drug, antibiotic, and biological drug product regulations; accelerated approval--FDA. Final rule.
    Fed Regist; 1992 Dec; 57(239):58942-60. PubMed ID: 10123232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulatory Oversight of Cell and Gene Therapy Products in Canada.
    Ridgway A; Agbanyo F; Wang J; Rosu-Myles M
    Adv Exp Med Biol; 2015; 871():49-71. PubMed ID: 26374212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reporting natural health product related adverse drug reactions: is it the pharmacist's responsibility?
    Walji R; Boon H; Barnes J; Welsh S; Austin Z; Baker GR
    Int J Pharm Pract; 2011 Dec; 19(6):383-91. PubMed ID: 22060233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmaceutical policies in Canada: another example of federal-provincial discord.
    Anis AH
    CMAJ; 2000 Feb; 162(4):523-6. PubMed ID: 10701389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.